Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 23, 2013

View Archived Issues

Fibulin-1 studied as a marker of idiopathic pulmonary fibrosis

Cures Within Reach and BioMotiv form partnership with focus on repurposing

Array BioPharma and Genentech prepare and test novel ERK inhibitors

Lead Discovery Center divulges series of CDK7 inhibitors

FPI-1465 resensitizes resistant strains to beta-lactam antibiotics

Cellceutix and the University of Pennsylvania design new compounds for malaria

Genentech presents data on Nampt inhibitors

Tolero details identification of novel PKM2 activators

Isis Pharmaceuticals reports follow-up data from phase I ISIS-SMNRx trial

OncoMed Pharmaceuticals begins phase Ib/II trial of demcizumab in ovarian cancer

Improvement of whole body glucose metabolism with a novel class of GPR40 agonists

Nesp 5-mcg plastic syringe injection approved in Japan

Photodynamic therapy agent Laserphyrin approved for new indication in Japan

TONIX Pharmaceuticals begins enrollment in phase IIb BESTFIT trial in fibromyalgia

EMA committee issues positive opinion on AstraZeneca's four-strain flu vaccine

Omeros begins phase II trial of OMS-824 in patients with stable schizophrenia

Ascendis Pharma begins dosing of human growth hormone product in phase II pediatric study

Otsuka and Lundbeck receive positive CHMP opinion for Abilify Maintena

Novo Nordisk's NovoEight gets positive opinion in E.U.

VIVUS requests scientific advice from EMA regarding MAA for Qsiva in obesity

GSK and Prosensa report failure of phase III study of drisapersen in DMD to meet primary endpoint

CHMP recommends E.U. approval of canagliflozin

Trastuzumab emtansine receives committee recommendation in E.U.

EMA committee recommends approval of Xofigo injection for CRPC

Takeda reports development of muscarinic M1 receptor allosteric modulators

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...